71 research outputs found

    A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa

    Get PDF
    BACKGROUND: In sub-Saharan Africa, the burden of human immunodeficiency virus (HIV)-associated tuberculosis is high. We conducted a trial with a 2-by-2 factorial design to assess the benefits of early antiretroviral therapy (ART), 6-month isoniazid preventive therapy (IPT), or both among HIV-infected adults with high CD4+ cell counts in Ivory Coast. METHODS: We included participants who had HIV type 1 infection and a CD4+ count of less than 800 cells per cubic millimeter and who met no criteria for starting ART according to World Health Organization (WHO) guidelines. Participants were randomly assigned to one of four treatment groups: deferred ART (ART initiation according to WHO criteria), deferred ART plus IPT, early ART (immediate ART initiation), or early ART plus IPT. The primary end point was a composite of diseases included in the case definition of the acquired immunodeficiency syndrome (AIDS), non-AIDS-defining cancer, non-AIDS-defining invasive bacterial disease, or death from any cause at 30 months. We used Cox proportional models to compare outcomes between the deferred-ART and early-ART strategies and between the IPT and no-IPT strategies. RESULTS: A total of 2056 patients (41% with a baseline CD4+ count of ≥500 cells per cubic millimeter) were followed for 4757 patient-years. A total of 204 primary end-point events were observed (3.8 events per 100 person-years; 95% confidence interval [CI], 3.3 to 4.4), including 68 in patients with a baseline CD4+ count of at least 500 cells per cubic millimeter (3.2 events per 100 person-years; 95% CI, 2.4 to 4.0). Tuberculosis and invasive bacterial diseases accounted for 42% and 27% of primary end-point events, respectively. The risk of death or severe HIV-related illness was lower with early ART than with deferred ART (adjusted hazard ratio, 0.56; 95% CI, 0.41 to 0.76; adjusted hazard ratio among patients with a baseline CD4+ count of ≥500 cells per cubic millimeter, 0.56; 95% CI, 0.33 to 0.94) and lower with IPT than with no IPT (adjusted hazard ratio, 0.65; 95% CI, 0.48 to 0.88; adjusted hazard ratio among patients with a baseline CD4+ count of ≥500 cells per cubic millimeter, 0.61; 95% CI, 0.36 to 1.01). The 30-month probability of grade 3 or 4 adverse events did not differ significantly among the strategies. CONCLUSIONS: In this African country, immediate ART and 6 months of IPT independently led to lower rates of severe illness than did deferred ART and no IPT, both overall and among patients with CD4+ counts of at least 500 cells per cubic millimeter. (Funded by the French National Agency for Research on AIDS and Viral Hepatitis; TEMPRANO ANRS 12136 ClinicalTrials.gov number, NCT00495651.)

    Study of e+eppˉe^+e^- \rightarrow p\bar{p} in the vicinity of ψ(3770)\psi(3770)

    Full text link
    Using 2917 pb1\rm{pb}^{-1} of data accumulated at 3.773~GeV\rm{GeV}, 44.5~pb1\rm{pb}^{-1} of data accumulated at 3.65~GeV\rm{GeV} and data accumulated during a ψ(3770)\psi(3770) line-shape scan with the BESIII detector, the reaction e+eppˉe^+e^-\rightarrow p\bar{p} is studied considering a possible interference between resonant and continuum amplitudes. The cross section of e+eψ(3770)ppˉe^+e^-\rightarrow\psi(3770)\rightarrow p\bar{p}, σ(e+eψ(3770)ppˉ)\sigma(e^+e^-\rightarrow\psi(3770)\rightarrow p\bar{p}), is found to have two solutions, determined to be (0.059±0.032±0.0120.059\pm0.032\pm0.012) pb with the phase angle ϕ=(255.8±37.9±4.8)\phi = (255.8\pm37.9\pm4.8)^\circ (<<0.11 pb at the 90% confidence level), or σ(e+eψ(3770)ppˉ)=(2.57±0.12±0.12\sigma(e^+e^-\rightarrow\psi(3770)\rightarrow p\bar{p}) = (2.57\pm0.12\pm0.12) pb with ϕ=(266.9±6.1±0.9)\phi = (266.9\pm6.1\pm0.9)^\circ both of which agree with a destructive interference. Using the obtained cross section of ψ(3770)ppˉ\psi(3770)\rightarrow p\bar{p}, the cross section of ppˉψ(3770)p\bar{p}\rightarrow \psi(3770), which is useful information for the future PANDA experiment, is estimated to be either (9.8±5.79.8\pm5.7) nb (<17.2<17.2 nb at 90% C.L.) or (425.6±42.9)(425.6\pm42.9) nb

    Search for single production of vector-like quarks decaying into a b quark and a W boson in proton-proton collisions at root s=13 TeV

    Get PDF
    Peer reviewe

    Observation of top quark pairs produced in association with a vector boson in pp collisions at s=8 √s=8TeV

    Get PDF
    Measurements of the cross sections for top quark pairs produced in association with a W or Z boson are presented, using 8 TeV pp collision data corresponding to an integrated luminosity of 19.5 fb −1 , collected by the CMS experiment at the LHC. Final states are selected in which the associated W boson decays to a charged lepton and a neutrino or the Z boson decays to two charged leptons. Signal events are identified by matching reconstructed objects in the detector to specific final state particles from t t ¯ W tt¯W or t t ¯ Z tt¯Z decays. The t t ¯ W tt¯W cross section is measured to be 382 − 102 + 117 fb with a significance of 4.8 standard deviations from the background-only hypothesis. The t t ¯ Z tt¯Z cross section is measured to be 242 − 55 + 65 fb with a significance of 6.4 standard deviations from the background-only hypothesis. These measurements are used to set bounds on five anomalous dimension-six operators that would affect the t t ¯ W tt¯W and t t ¯ Z tt¯Z cross sections

    Search for new long-lived particles at root s=13 TeV

    Get PDF
    A search for long-lived particles was performed with data corresponding to an integrated luminosity of 2.6 fb(-1) collected at a center-of-mass energy of 13 TeV by the CMS experiment in 2015. The analysis exploits two customized topological trigger algorithms, and uses the multiplicity of displaced jets to search for the presence of a signal decay occurring at distances between 1 and 1000 mm. The results can be interpreted in a variety of different models. For pair-produced long-lived particles decaying to two b quarks and two leptons with equal decay rates between lepton flavors, cross sections larger than 2.5 fb are excluded for proper decay lengths between 70-100 mm for a long-lived particle mass of 1130 GeV at 95% confidence. For a specific model of pair-produced, long-lived top squarks with R-parity violating decays to a b quark and a lepton, masses below 550-1130 GeV are excluded at 95% confidence for equal branching fractions between lepton flavors, depending on the squark decay length. This mass bound is the most stringent to date for top squark proper decay lengths greater than 3 mm. (C) 2018 The Author(s). Published by Elsevier B.V.Peer reviewe

    Pseudorapidity dependence of long-range two-particle correlations in pPb collisions at root sNN=5.02 TeV

    Get PDF
    Peer reviewe

    Coherent J/psi photoproduction in ultra-peripheral PbPb collisions at root s(NN)=2.76 TeV with the CMS experiment

    Get PDF
    Peer reviewe

    Upsilon (nS) polarizations versus particle multiplicity in pp collisions at root s=7 TeV

    Get PDF
    Peer reviewe

    Observation of the Higgs boson decay to a pair of tau leptons with the CMS detector

    Get PDF
    A measurement of the H -> tau tau signal strength is performed using events recorded in proton-proton collisions by the CMS experiment at the LHC in 2016 at a center-of-mass energy of 13TeV. The data set corresponds to an integrated luminosity of 35.9 fb(-1). The H -> tau tau signal is established with a significance of 4.9 standard deviations, to be compared to an expected significance of 4.7 standard deviations. The best fit of the product of the observed H -> tau tau signal production cross section and branching fraction is 1.09(-0.2)(6+0.27) times the standard model expectation. The combination with the corresponding measurement performed with data collected by the CMS experiment at center-of-mass energies of 7 and 8 TeV leads to an observed significance of 5.9 standard deviations, equal to the expected significance. This is the first observation of Higgs boson decays to tau leptons by a single experiment. (c) 2018 The Author(s). Published by Elsevier B.V.Peer reviewe
    corecore